Keywords
kidney transplant
COVID-19
How to Cite
Abstract
169 patients with a functioning kidney transplant were observed. In 51 patients from 169 were diagnosed with COVID-19. The virus was verified by polymerase chain reaction in all patients and in 74% of cases immunoglobulins M and G were detected by immunological blood tests. Patients who underwent COVID-19 were divided into the following groups: Group 1 – kidney transplant recipients who recovered after COVID-19 (n=44); Group 2 – kidney transplant recipients who died (n=7). Lymphopenia, which was directly proportional to the severity of the disease, was observed in Group 2 patients. The serum C-reactive protein content of Group 2 patients did not differ significantly from that of Group 1. In Group 2 patients, the D-dimer content was significantly higher than that of Group 1. When we analyzed the percentage of lung lesions of the examined patients, it was found that in patients of Group 2 this figure was 68.0 [63.5; 75.0], which was probably higher than that of Group 1 patients (p<0.05). Kidney transplant dysfunction was observed in 16 recipients (31%) during the follow-up period of patients with COVID-19. Complications observed during the disease and arising from the treatment of patients accounted for 15.2%, of which thrombosis of various localizations – 1.5%, myocardial damage – 2.5%, bleeding – 3.4%. The mortality rate of kidney transplant recipients was 13.7%. The main cause of death was acute respiratory syndrome in combination with sepsis (in 8.1% of patients), pulmonary embolism (in 3.2%), and acute cerebrovascular accident (in 2.4%). According to our studies, the risk factors for an unfavorable outcome of COVID-19 are comorbid syndrome, the severity of lung damage, hyperalbuminuria, an increase in C-reactive protein, D-dimer, platelets and lymphopenia.
Keywords: chronic kidney disease, kidney transplant, COVID-19.
References
Toapanta N, Torres IB, Sellarés J, Chamoun B, Serón D, Moreso F. Kidney transplan-tation and COVID-19 renal and patient prognosis. Clin Kidney J. 2021;14(Suppl 1):i21–9. DOI: 10.1093/ckj/sfab030. PMID: 33815780; PMCID: PMC7995521.
Pascual J, Melilli E, Jiménez-Martín C, González-Monte E, Zárraga S, Gutiérrez-Dalmau A, et al. COVID-19-related mortality during the first 60 days after kidney transplan-tation. Eur Urol. 2020;78(4):641–3. DOI: 10.1016/j.eururo.2020.06.036. PMID: 32624283. PMCID: PMC7303649.
Elens L, Langman LJ, Hesselink DA, Bergan S, Moes DJAR, Molinaro M, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. Ther Drug Monit. 2020;42(3):360–8. DOI: 10.1097/FTD.0000000000000761. PMID: 32304488. PMCID: PMC7188032.
Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dial-ysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540–8. DOI: 10.1016/j.kint.2020.09.006. PMID: 32979369. PMCID: PMC7560263.
Rodriguez-Cubillo B, de la Higuera MAM, Lucena R, Franci EV, Hurtado M, Romero NC, et al. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2. Am J Transplant. 2020;20(11):3173–81. DOI: 10.1111/ajt.16141. PMID: 32529737. PMCID: PMC7307110.
De Meester J, De Bacquer D, Naesens M, Meijers B, Couttenye MM, De Vriese AS; NBVN Kidney Registry Group. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study. J Am Soc Nephrol. 2020;32(2):385–96. DOI: 10.1681/ASN.2020060875. PMID: 33154174. PMCID: PMC8054894.
Mamode N, Ahmed Z, Jones G, Banga N, Motallebzadeh R, Tolley H, et al. Mortali-ty rates in transplant recipients and transplantation candidates in a high prevalence COVID-19 environment. Transplantation. 2020;105(1):212–5. DOI: 10.1097/TP.0000000000003533. PMID: 33196624.